Abstract Purpose: Immune-mediated graft-versus-tumor (GVT) effects can occur after allogeneic hematopoietic stem cell transplantation (HSCT), but GVT is tightly linked to its main complication, graft-versus-host disease (GVHD). Strategies aimed at modulating GVHD, while maintaining the effect, are needed improve cure rate of transplant. Given emerging role Janus-activated kinase (JAK) signaling in lymphoproliferative and myeloproliferative diseases established function dictating T-cell...

Recombinant peptides have the power to harness inherent biocompatibility of natural macromolecules, while maintaining a defined chemistry for use in tissue engineering. Creating scaffolds from requires stabilization via crosslinking, process known alter both mechanics and density adhesion ligands. The linear recombinant peptide based on human collagen type I (RCP) was investigated after crosslinking. Three treatments were compared: dehydrothermal treatment (DHT), hexamethylene diisocyanate...

The development of scaffold formulations based on extracellular matrix (ECM)-inspired synthetic materials constitutes an important resource for the advance cell-based therapies in bone tissue engineering approaches, where both cell and implantation are often needed. Culturing cells porous microcarriers (MCs) allows expansion a three-dimensional microenvironment possible solution minimally invasive simultaneous delivery, but reduced pore dimension interconnection diameter several commercially...

Tissue engineering is a promising field, focused on developing solutions for the increasing demand tissues and organs regarding transplantation purposes. The process to generate such complex, includes an appropriate combination of specific cell types, scaffolds, physical or biochemical stimuli guide growth differentiation. Microcarriers represent appealing tool expand cells in three-dimensional (3D) microenvironment, since they provide higher surface-to volume ratios mimic more closely vivo...

Tissue engineering is a promising field, focused on developing solutions for the increasing demand tissues and organs regarding transplantation purposes. The process to generate such complex, includes an appropriate combination of specific cell types, scaffolds, physical or biochemical stimuli guide growth differentiation. Microcarriers represent appealing tool expand cells in three-dimensional (3D) microenvironment, since they provide higher surface-to volume ratios mimic more closely vivo...

Event Abstract Back to Osteogenic differentiation modulated by cross-linking of tissue engineering scaffolds Kendell Pawelec1, Davide Confalonieri2*, Franziska Ehlicke2*, Heike Walles2* and Sebastiaan G. Kluijtmans1* 1 FUJIFILM Europe B.V., Netherlands 2 Fraunhofer Institute for Interfacial Engineering Biotechnology IGB, Germany Introduction: Stem cells can be induced towards an osteogenic lineage a number factors, not the least which are mechanical properties their surrounding...

<p>Supplementary Figures S1-6. Figure S1: Histological staging criteria for acute GvHD S2: Ruxolitinib does not impair post-transplant donor myeloid reconstitution and full chimerism. S3: GVT effect against leukemia RMB-1 cell line is maintained in the presence of ruxolitinib S4: at dose 90 mg/Kg prevents GVHD without affecting T alloreactivity S5: 45 on absolute numbers alloreactive cells, Th17 Treg cells. S6: Representative Images Ruxolitinb cells macrophage infiltration organs</p>

<div>Abstract<p><b>Purpose:</b> Immune-mediated graft-versus-tumor (GVT) effects can occur after allogeneic hematopoietic stem cell transplantation (HSCT), but GVT is tightly linked to its main complication, graft-versus-host disease (GVHD). Strategies aimed at modulating GVHD, while maintaining the effect, are needed improve cure rate of transplant. Given emerging role Janus-activated kinase (JAK) signaling in lymphoproliferative and myeloproliferative diseases...

<div>Abstract<p><b>Purpose:</b> Immune-mediated graft-versus-tumor (GVT) effects can occur after allogeneic hematopoietic stem cell transplantation (HSCT), but GVT is tightly linked to its main complication, graft-versus-host disease (GVHD). Strategies aimed at modulating GVHD, while maintaining the effect, are needed improve cure rate of transplant. Given emerging role Janus-activated kinase (JAK) signaling in lymphoproliferative and myeloproliferative diseases...

<p>Supplementary Figures S1-6. Figure S1: Histological staging criteria for acute GvHD S2: Ruxolitinib does not impair post-transplant donor myeloid reconstitution and full chimerism. S3: GVT effect against leukemia RMB-1 cell line is maintained in the presence of ruxolitinib S4: at dose 90 mg/Kg prevents GVHD without affecting T alloreactivity S5: 45 on absolute numbers alloreactive cells, Th17 Treg cells. S6: Representative Images Ruxolitinb cells macrophage infiltration organs</p>